Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzylhydrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.54 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | IDO1 | P14902 | 3/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylhydrazine SCHEMBL176887 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL29080870 | 0.97 | CYP3A4 (0.95) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL28071597 | 0.97 | CYP3A4 (0.95) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL176979 | 0.97 | — | — | |
| Benzylhydrazine SCHEMBL8861708 | 0.94 | IDO1 (0.94) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL28389744 | 0.94 | IDO1 (0.94) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL27509884 | 0.94 | IDO1 (0.94) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL10436051 | 0.94 | IDO1 (0.94) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL27529745 | 0.94 | IDO1 (0.94) | CYP3A4MAPTIDO1KDM4ELMNA | |
| Benzylhydrazine SCHEMBL697342 | 0.92 | IDO1 (0.90) | CYP3A4MAPTIDO1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 868 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | claimed |
| CN-117042571-A | Perovskite film additive, perovskite solar cell and preparation method of perovskite film additive | 上海乐天钙钛光电科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-10329264-B2 | Process for the preparation of isocarboxazid | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2019-06-25 | — | — | US | claimed |
| EP-3328842-B1 | PROCESS FOR THE PREPARATION OF ISOCARBOXAZID | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2019-06-12 | — | — | EP | claimed |
| US-20180215722-A1 | PROCESS FOR THE PREPARATION OF ISOCARBOXAZID | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2018-08-02 | — | — | US | claimed |
| EP-3328842-A1 | PROCESS FOR THE PREPARATION OF ISOCARBOXAZID | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2018-06-06 | — | — | EP | claimed |
| WO-2017021246-A1 | PROCESS FOR THE PREPARATION OF ISOCARBOXAZID | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2017-02-09 | — | — | WO | claimed |
| CN-102617472-A | Preparation method of tetra-substituted olefin and pyrazole derivative thereof | DALIAN CHEMICAL PHYSICS INST | 2012-08-01 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| US-4041046-A | INTERMEDIATES FOR THE CORRESPONDING HERBICIDAL PYRAZOLIUM SALTS ON | AMERICAN CYANAMID COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-4009277-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-4000301-A | Fungicidal use of 4-alkoxypyrazoles | AMERICAN CYANAMID COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3963742-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | MAOA 485/4885HTR1A 269/4885ADRA2A 22/4885 |
| US-20180215722-A1 | PROCESS FOR THE PREPARATION OF ISOCARBOXAZID | IDH2, IDH1, IDH3A | MAOA 978/4885HTR1A 3732/4885ADRA2A 2961/4885 |
| US-10329264-B2 | Process for the preparation of isocarboxazid | IDH2, IDH1, IDH3A | MAOA 978/4885HTR1A 3732/4885ADRA2A 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.